Advances in the treatment of hematologic malignancies using immunoconjugates
about
Structure-based design and synthesis of a bivalent iminobiotin analog showing strong affinity toward a low immunogenic streptavidin mutantStructure-based design of a streptavidin mutant specific for an artificial biotin analogueAGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AMLWhole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityBortezomib for the treatment of non-Hodgkin's lymphomaA rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.Targeted therapies for cutaneous T-cell lymphomas.Immune-based therapies for childhood cancer.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.Immunotherapy for the treatment of Hodgkin lymphoma.New targeted therapies for malignant lymphoma based on molecular heterogeneity.The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer.(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
P2860
Q27697299-2753B337-3ADC-47BF-9EB2-9FC8A03F8834Q27697883-FC3AC46D-79A9-44BA-9E8B-BFC7417B5976Q30403563-0664D5D4-F06B-459E-8570-0B8208FC8862Q35189855-1C09A000-83E1-496D-B205-DCA03A6A78FEQ36868056-BC928BAE-251F-4395-9FE4-F8041ADDD929Q37138223-5B812CC7-180B-4B60-BB80-2BA8FDEAAE29Q38229634-D4A44224-8C1B-400C-AF81-57018D62AC9AQ38263108-5C5BDC8D-78CA-44C0-863E-2E4D21CD0CE5Q38550992-1D024595-B3F8-412E-A955-AFA6C3680CB5Q38737641-51370639-A708-4E99-B990-0FFEAD1046AEQ38787141-97CA10F3-7847-4FB0-A97C-9663BE4CE407Q39338052-67497A14-0B9E-4695-BAA6-3AFD3EBC0796Q41005562-3D3DF1BD-C695-4B4E-BAFF-ECBE7478EE2CQ48541938-6165657F-20CE-43B3-BA54-3F363B77A1DBQ52685422-A308F53C-D6EC-431B-9770-C43E3E916FFCQ52780137-A241B7CB-6713-4E52-8EAD-869495A5AA8B
P2860
Advances in the treatment of hematologic malignancies using immunoconjugates
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Advances in the treatment of hematologic malignancies using immunoconjugates
@en
Advances in the treatment of hematologic malignancies using immunoconjugates.
@nl
type
label
Advances in the treatment of hematologic malignancies using immunoconjugates
@en
Advances in the treatment of hematologic malignancies using immunoconjugates.
@nl
prefLabel
Advances in the treatment of hematologic malignancies using immunoconjugates
@en
Advances in the treatment of hematologic malignancies using immunoconjugates.
@nl
P2860
P1433
P1476
Advances in the treatment of hematologic malignancies using immunoconjugates
@en
P2093
Maria Corinna Palanca-Wessels
P2860
P304
P356
10.1182/BLOOD-2013-10-492223
P407
P577
2014-02-27T00:00:00Z